News

Biotech venture capital is risky business, inherently at the mercy of regulators and binary outcomes. Now it may face a new ...
CBER’s new chief has argued for more stringent measures of assessing drugs for cancer and rare diseases, suggesting he might ...
WASHINGTON — In his first address to FDA staff on Wednesday, Vinay Prasad emphasized his commitment to evidence, his ...
The U.S. Food and Drug Administration has named Vinay Prasad, an oncologist who has previously criticized the FDA and was a ...